SCHEMBL5222966

SCHEMBL5222966

COc1cccc(C(=O)c2ccc(Br)cc2C(=O)N(C)CCO)c1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
MAPT P10636 4/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
KCNH2 Q12809 1/20 0.38
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
STAT3 P40763 1/20 0.38
UTS2R Q9UKP6 2/20 0.37
POLB P06746 3/20 0.37
CDK4 P11802 1/20 0.37
CCND1 P24385 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ABCB1 P08183 1/20 0.37
GYS1 P13807 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4679801 0.90 CDK4 (0.43) KDM4EMAPTNPC1RAB9APOLB
SCHEMBL4679118 0.85 CDK4 (0.43) KDM4EMAPTNPC1RAB9APOLB
SCHEMBL5153378 0.80 CDC25B (0.48) KDM4ERXFP1MAPTNPC1RAB9A
SCHEMBL21177597 0.80 POLB (0.48) KDM4ERXFP1MAPTSTAT3POLB
SCHEMBL4679798 0.79 CYP2C8 (0.46) POLBCDK4CCND1MEN1KMT2A
SCHEMBL5153184 0.78 CDC25B (0.48) KDM4ERXFP1MAPTNPC1RAB9A
SCHEMBL4682844 0.77 MAPT (0.50) KDM4ERXFP1MAPTNPC1RAB9A
SCHEMBL4707506 0.77 MAPT (0.51) MAPTPOLBCDK4CCND1MEN1
SCHEMBL4118366 0.75 KDM4E (0.46) KDM4ERXFP1MAPTNPC1RAB9A
SCHEMBL4679115 0.75 CYP2C8 (0.46) POLBCDK4CCND1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740558-A1 BENZOXAZOCINES AND THEIR THERAPEUTIC USE AS MONOAMINE REUPTAKE INHIBITORS Sosei R&D Ltd. (GB) 2007-01-10 EP disclosed
US-20060019940-A1 Novel benzoxazocines and their therapeutic use SOSEI R&D LTD. (GB) 2006-01-26 US disclosed
WO-2005103019-A1 BENZOXAZOCINES AND THEIR THERAPEUTIC USE AS MONOAMINE REUPTAKE INHIBITORS SOSEI R&D LTD. (GB) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019940-A1 Novel benzoxazocines and their therapeutic use HTR4, OPRM1, GRM4 KDM4E 461/4885RXFP1 466/4885MAPT 3319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.